The Transport Pathway in the ABCG2 Protein and Its Regulation Revealed by Molecular Dynamics Simulations

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2020 Sep 26

PMID 32979053

Citations 10

Authors

Tamas Nagy

Agota Toth

Agnes Telbisz

Balazs Sarkadi

Hedvig Tordai

Attila Tordai

Tamas Hegedus

Affiliations

Soon will be listed here.

Abstract

Atomic-level structural insight on the human ABCG2 membrane protein, a pharmacologically important transporter, has been recently revealed by several key papers. In spite of the wealth of structural data, the pathway of transmembrane movement for the large variety of structurally different ABCG2 substrates and the physiological lipid regulation of the transporter has not been elucidated. The complex molecular dynamics simulations presented here may provide a breakthrough in understanding the steps of the substrate transport process and its regulation by cholesterol. Our analysis revealed drug binding cavities other than the central binding site and delineated a putative dynamic transport pathway for substrates with variable structures. We found that membrane cholesterol accelerated drug transport by promoting the closure of cytoplasmic protein regions. Since ABCG2 is present in all major biological barriers and drug-metabolizing organs, influences the pharmacokinetics of numerous clinically applied drugs, and plays a key role in uric acid extrusion, this information may significantly promote a reliable prediction of clinically important substrate characteristics and drug-drug interactions.

Citing Articles

ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches.

Elbahnsi A, Dudas B, Callebaut I, Hinzpeter A, Miteva M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770445 PMC: 11676857. DOI: 10.3390/ph17121602.

Membrane-assisted tariquidar access and binding mechanisms of human ATP-binding cassette transporter P-glycoprotein.

Gao Y, Wei C, Luo L, Tang Y, Yu Y, Li Y Front Mol Biosci. 2024; 11:1364494.

PMID: 38560519 PMC: 10979361. DOI: 10.3389/fmolb.2024.1364494.

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).

da Silva Zanzarini I, Henrique Kita D, Scheiffer G, Karoline Dos Santos K, de Paula Dutra J, Augusto Pastore M Bioorg Chem. 2024; 146:107283.

PMID: 38513324 PMC: 11069345. DOI: 10.1016/j.bioorg.2024.107283.

Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors.

de Paula Dutra J, Scheiffer G, Kronenberger T, Gomes L, Zanzarini I, Karoline Dos Santos K EXCLI J. 2024; 22:1155-1172.

PMID: 38204967 PMC: 10776880. DOI: 10.17179/excli2023-6427.

Restriction of access to the central cavity is a major contributor to substrate selectivity in plant ABCG transporters.

Pakula K, Sequeiros-Borja C, Biala-Leonhard W, Pawela A, Banasiak J, Bailly A Cell Mol Life Sci. 2023; 80(4):105.

PMID: 36952129 PMC: 10036432. DOI: 10.1007/s00018-023-04751-6.

References

Galvan-Hernandez A, Kobayashi N, Hernandez-Cobos J, Antillon A, Nakabayashi S, Ortega-Blake I . Morphology and dynamics of domains in ergosterol or cholesterol containing membranes. Biochim Biophys Acta Biomembr. 2019; 1862(2):183101. DOI: 10.1016/j.bbamem.2019.183101. View

Lomize M, Lomize A, Pogozheva I, Mosberg H . OPM: orientations of proteins in membranes database. Bioinformatics. 2006; 22(5):623-5. DOI: 10.1093/bioinformatics/btk023. View

Noguchi K, Katayama K, Sugimoto Y . Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 2014; 7:53-64. PMC: 3921828. DOI: 10.2147/PGPM.S38295. View

Khunweeraphong N, Stockner T, Kuchler K . The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion. Sci Rep. 2017; 7(1):13767. PMC: 5653816. DOI: 10.1038/s41598-017-11794-w. View

Manolaridis I, Jackson S, Taylor N, Kowal J, Stahlberg H, Locher K . Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states. Nature. 2018; 563(7731):426-430. PMC: 6379061. DOI: 10.1038/s41586-018-0680-3. View

Chen L, Hou W, Fan T, Liu B, Pan T, Li Y . Cryo-electron Microscopy Structure and Transport Mechanism of a Wall Teichoic Acid ABC Transporter. mBio. 2020; 11(2). PMC: 7078476. DOI: 10.1128/mBio.02749-19. View

van Meer G . Lipid traffic in animal cells. Annu Rev Cell Biol. 1989; 5:247-75. DOI: 10.1146/annurev.cb.05.110189.001335. View

Taylor N, Manolaridis I, Jackson S, Kowal J, Stahlberg H, Locher K . Structure of the human multidrug transporter ABCG2. Nature. 2017; 546(7659):504-509. DOI: 10.1038/nature22345. View

Lee J, Patel D, Stahle J, Park S, Kern N, Kim S . CHARMM-GUI Membrane Builder for Complex Biological Membrane Simulations with Glycolipids and Lipoglycans. J Chem Theory Comput. 2018; 15(1):775-786. DOI: 10.1021/acs.jctc.8b01066. View

10.

Gyimesi G, Ramachandran S, Kota P, Dokholyan N, Sarkadi B, Hegedus T . ATP hydrolysis at one of the two sites in ABC transporters initiates transport related conformational transitions. Biochim Biophys Acta. 2011; 1808(12):2954-64. DOI: 10.1016/j.bbamem.2011.07.038. View

11.

Hedger G, Sansom M . Lipid interaction sites on channels, transporters and receptors: Recent insights from molecular dynamics simulations. Biochim Biophys Acta. 2016; 1858(10):2390-2400. PMC: 5589069. DOI: 10.1016/j.bbamem.2016.02.037. View

12.

van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark A, Berendsen H . GROMACS: fast, flexible, and free. J Comput Chem. 2005; 26(16):1701-18. DOI: 10.1002/jcc.20291. View

13.

Allen W, Lemkul J, Bevan D . GridMAT-MD: a grid-based membrane analysis tool for use with molecular dynamics. J Comput Chem. 2008; 30(12):1952-8. DOI: 10.1002/jcc.21172. View

14.

Tordai H, Leveles I, Hegedus T . Molecular dynamics of the cryo-EM CFTR structure. Biochem Biophys Res Commun. 2017; 491(4):986-993. DOI: 10.1016/j.bbrc.2017.07.165. View

15.

Jackson S, Manolaridis I, Kowal J, Zechner M, Taylor N, Bause M . Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol Biol. 2018; 25(4):333-340. DOI: 10.1038/s41594-018-0049-1. View

16.

Michaud-Agrawal N, Denning E, Woolf T, Beckstein O . MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J Comput Chem. 2011; 32(10):2319-27. PMC: 3144279. DOI: 10.1002/jcc.21787. View

17.

Zamek-Gliszczynski M, Taub M, Chothe P, Chu X, Giacomini K, Kim R . Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clin Pharmacol Ther. 2018; 104(5):890-899. PMC: 8211378. DOI: 10.1002/cpt.1112. View

18.

Mozner O, Bartos Z, Zambo B, Homolya L, Hegedus T, Sarkadi B . Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism. Cells. 2019; 8(10). PMC: 6830335. DOI: 10.3390/cells8101215. View

19.

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

20.

Safar Z, Kis E, Erdo F, Zolnerciks J, Krajcsi P . ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol. 2019; 15(4):313-328. DOI: 10.1080/17425255.2019.1591373. View